혈장 분획 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Plasma Fractionation Market (Product Type: Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Other Plasma Products) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
상품코드:1459780
리서치사:Transparency Market Research
발행일:2024년 02월
페이지 정보:영문 194 Pages
라이선스 & 가격 (부가세 별도)
한글목차
혈장 분획 시장 - 조사 범위
TMR의 세계 혈장 분획 시장 조사 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고, 2023년을 기준 연도로, 2031년을 예측 연도로, 2017에서 2031년까지 세계 혈장 분획 시장의 수익과 예측을 제공합니다. 또한 2023년부터 2031년까지 세계 혈장 분획 시장의 복합 연간 성장률(CAGR%)도 제공합니다.
이 보고서는 광범위한 조사 끝에 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 문서를 참조하여 혈장 분획 시장을 이해하고자 했습니다. 참고했습니다.
시장 현황
2022년 시장 가치
241억 달러
2031년 시장 가치
426억 달러
CAGR
6.7%
이 보고서는 세계 혈장 분획 시장 경쟁 구도를 심층적으로 분석합니다. 세계 혈장 분획 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 시장 개발 및 SWOT는 이 보고서에서 다루는 세계 혈장 분획 시장의 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 혈장 분획 시장
제4장 시장 개요
서론
시장 개요
시장 역학
혈장 분획 시장 분석과 예측, 2017-2031년
제5장 주요 인사이트
파이프라인 분석
주요 기술/브랜드 분석
주요 M&A
COVID-19 팬데믹 업계에 대한 영향
제6장 혈장 분획 시장 분석과 예측 : 제품 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 제품 유형별, 2017년-2031년
면역글로불린
정주용 면역글로불린
피하 면역글로불린
응고인자 농축 제제
제VIII인자
제IX인자
제XIII인자
프로트롬빈 복합체 농축 제제
폰 필렌브란트 인자(VWF)
피브리노겐 농축물
알부민
프로테아제 억제제
기타 혈장 제품
시장의 매력 분석 : 제품 유형별
제7장 혈장 분획 시장 분석과 예측 : 용도별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 용도별, 2017-2031년
신경학
면역학
혈액학
중환자 치료
호흡기 내과
기타
시장의 매력 분석 : 용도별
제8장 혈장 분획 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 최종사용자별, 2017년-2031년
병원 및 클리닉
임상 연구소
학술기관
시장의 매력 분석 : 용도별
제9장 혈장 분획 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2017년-2031년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 북미의 혈장 분획 시장 분석과 예측
제11장 유럽의 혈장 분획 시장 분석과 예측
제12장 아시아태평양의 혈장 분획 시장 분석과 예측
제13장 라틴아메리카의 혈장 분획 시장 분석과 예측
제14장 중동 및 아프리카의 혈장 분획 시장 분석과 예측
제15장 경쟁 구도
시장 경쟁 : 경쟁 매트릭스(Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
CSL Limited
Takeda Pharmaceutical Company
Sanquin
Biotest AG
GRIFOLS
Baxter International Inc.
Kedrion
Octapharma AG
Taibang Biological Group Co., Ltd
LSH
영문 목차
영문목차
Plasma Fractionation Market - Scope of Report
TMR's report on the global plasma fractionation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global plasma fractionation market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global plasma fractionation market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the plasma fractionation market.
Market Snapshot
Market Value in 2022
US$ 24.1 Bn
Market Value in 2031
US$ 42.6 Bn
CAGR
6.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global plasma fractionation market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global plasma fractionation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global plasma fractionation market.
The report delves into the competitive landscape of the global plasma fractionation market. Key players operating in the global plasma fractionation market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global plasma fractionation market profiled in this report.
Key Questions Answered in Global plasma fractionation Market Report:
What is the sales/revenue generated by plasma fractionation across all regions during the forecast period?
What are the opportunities in the global plasma fractionation market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Plasma Fractionation Market - Research Objectives and Research Approach
The comprehensive report on the global plasma fractionation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global plasma fractionation market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global plasma fractionation market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Plasma Fractionation Market
4. Market Overview
4.1. Introduction
4.1.1. Technology, Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Plasma Fractionation Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology, /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.4. Market Attractiveness Analysis, by Product Type,
7. Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Neurology
7.3.2. Immunology
7.3.3. Hematology
7.3.4. Critical Care
7.3.5. Pulmonology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals and Clinics
8.3.2. Clinical Research Laboratories
8.3.3. Academic Institutes
8.4. Market Attractiveness Analysis, by Application
9. Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017-2031
10.3.1. Immunoglobulin
10.3.1.1. Intravenous Immunoglobulin
10.3.1.2. Subcutaneous Immunoglobulin
10.3.2. Coagulation Factor Concentrates
10.3.2.1. Factor VIII
10.3.2.2. Factor IX
10.3.2.3. Factor XIII
10.3.2.4. Prothrombin Complex Concentrates
10.3.2.5. Von Willebrand Factor (VWF)
10.3.2.6. Fibrinogen Concentrates
10.3.3. Albumin
10.3.4. Protease Inhibitors
10.3.5. Other Plasma Products
10.4. Market Value Forecast, by Application, 2017-2031
10.4.1. Neurology
10.4.2. Immunology
10.4.3. Hematology
10.4.4. Critical Care
10.4.5. Pulmonology
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2017-2031
10.5.1. Hospitals and Clinics
10.5.2. Clinical Research Laboratories
10.5.3. Academic Institutes
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type,
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017-2031
11.3.1. Immunoglobulin
11.3.1.1. Intravenous Immunoglobulin
11.3.1.2. Subcutaneous Immunoglobulin
11.3.2. Coagulation Factor Concentrates
11.3.2.1. Factor VIII
11.3.2.2. Factor IX
11.3.2.3. Factor XIII
11.3.2.4. Prothrombin Complex Concentrates
11.3.2.5. Von Willebrand Factor (VWF)
11.3.2.6. Fibrinogen Concentrates
11.3.3. Albumin
11.3.4. Protease Inhibitors
11.3.5. Other Plasma Products
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Neurology
11.4.2. Immunology
11.4.3. Hematology
11.4.4. Critical Care
11.4.5. Pulmonology
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals and Clinics
11.5.2. Clinical Research Laboratories
11.5.3. Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017-2031
12.3.1. Immunoglobulin
12.3.1.1. Intravenous Immunoglobulin
12.3.1.2. Subcutaneous Immunoglobulin
12.3.2. Coagulation Factor Concentrates
12.3.2.1. Factor VIII
12.3.2.2. Factor IX
12.3.2.3. Factor XIII
12.3.2.4. Prothrombin Complex Concentrates
12.3.2.5. Von Willebrand Factor (VWF)
12.3.2.6. Fibrinogen Concentrates
12.3.3. Albumin
12.3.4. Protease Inhibitors
12.3.5. Other Plasma Products
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Neurology
12.4.2. Immunology
12.4.3. Hematology
12.4.4. Critical Care
12.4.5. Pulmonology
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals and Clinics
12.5.2. Clinical Research Laboratories
12.5.3. Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type,
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017-2031
13.3.1. Immunoglobulin
13.3.1.1. Intravenous Immunoglobulin
13.3.1.2. Subcutaneous Immunoglobulin
13.3.2. Coagulation Factor Concentrates
13.3.2.1. Factor VIII
13.3.2.2. Factor IX
13.3.2.3. Factor XIII
13.3.2.4. Prothrombin Complex Concentrates
13.3.2.5. Von Willebrand Factor (VWF)
13.3.2.6. Fibrinogen Concentrates
13.3.3. Albumin
13.3.4. Protease Inhibitors
13.3.5. Other Plasma Products
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Neurology
13.4.2. Immunology
13.4.3. Hematology
13.4.4. Critical Care
13.4.5. Pulmonology
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals and Clinics
13.5.2. Clinical Research Laboratories
13.5.3. Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type,
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017-2031
14.3.1. Immunoglobulin
14.3.1.1. Intravenous Immunoglobulin
14.3.1.2. Subcutaneous Immunoglobulin
14.3.2. Coagulation Factor Concentrates
14.3.2.1. Factor VIII
14.3.2.2. Factor IX
14.3.2.3. Factor XIII
14.3.2.4. Prothrombin Complex Concentrates
14.3.2.5. Von Willebrand Factor (VWF)
14.3.2.6. Fibrinogen Concentrates
14.3.3. Albumin
14.3.4. Protease Inhibitors
14.3.5. Other Plasma Products
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Neurology
14.4.2. Immunology
14.4.3. Hematology
14.4.4. Critical Care
14.4.5. Pulmonology
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals and Clinics
14.5.2. Clinical Research Laboratories
14.5.3. Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type,
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
